Clinical trials: Obesity in Diabetes
Type 2 Diabetes Mellitus (T2DM)
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
- Trial name
- NCT05761301
- Testing
- ALN-KHK
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes Mellitus, Obesity
Form of Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Young and Older Adults
The proposed study is planned to determine the potential role for regular fat dairy products in short-term metabolic control in younger and older adults and the metabolic flexibility in response to food components, which are…
- Trial name
- NCT02491801
- Testing
- Dietary intervention
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Low Carbohydrate Diet in Diabetic Kidney Disease
The current population of type 2 diabetes mellitus (T2DM) worldwide is over 200 million and Malaysia contributes to 1.2% of that number.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Obesity
- Trial name
- NCT04931030
- Testing
- Dietary advice
- Where
- Malaysia
- Volunteers
- 30 people
- Sponsor
- Universiti Teknologi Mara
Non-diabetec Obesity, Obesity (Disorder)
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults.
- Trial name
- NCT07834398
- Testing
- Dulaglutide, Semagludtide, Tirzepatide
- Where
- Saudi Arabia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Obesity, Overweight
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
- Trial name
- MARITIME-PEN (NCT07871409)
- Testing
- Maridebart cafraglutide, Autoinjector
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Amgen
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.
- Conditions
- Obesity, Overweight, Metabolism and Nutrition Disorder
- Trial name
- SURMOUNT-CN (NCT05024032)
- Testing
- Tirzepatide
- Where
- 29 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and…
- Trial name
- MEASURE (NCT07639684)
- Testing
- ESG with OverStitch
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Childhood Obesity, Overweight and Obesity
Childhood Obesity - Prevention of Diabetes Through Changed Eating Patterns
The main purpose of the present study is to perform a 10 weeks dietary intervention study with a follow-up for 52 weeks in children from 7-14 years of age with overweight or obesity.
- Conditions
- Childhood Obesity, Overweight and Obesity, Adolescent Obesity, Adolescent Overweight
- Trial name
- COPE (NCT04522921)
- Testing
- Diet with a higher amount of protein (25E% per day), Increased follow-up contact after the 10-week intervention, Diet with a lower amount of protein (15E% per day)
- Where
- 2 sites in Denmark
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Obesity
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid…
- Trial name
- NCT07247084
- Testing
- Tirzepatide, Standard of Care
- Where
- 30 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
C-Reactive Protein (CRP) in Obese Diabetic Women
The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.
- Trial name
- NCT00262548
- Testing
- Rosuvastatin; improvement of lipid profile
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Obesity, Diabetes
The Effects of Carbohydrate Source on Food Intake, Blood Glucose and Gut Hormone Response in Healthy Children
This study will compare the effects of commonly consumed carbohydrate sources such as potatoes, pasta and rice along with a fixed portion of meat on blood glucose, satiety and insulin levels among healthy body weight children.
- Trial name
- NCT02499107
- Testing
- Rice treatment, Pasta treatment, Boiled and mashed potato treatment
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Type 2 Diabetes Mellitus
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A Phase 2 study with two cohorts of differing doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03244800
- Testing
- MEDI0382
- Where
- 5 sites in Germany
- Volunteers
- 65 people
- Sponsor
- MedImmune LLC
Obesity, Prediabetes
The Effect of Time-Restricted Eating in 24-hour Metabolic Homeostasis and Diurnal Rhythm
Time-restricted eating (TRE) is a dietary manipulation that involves restricting food intake to 6-12 h/day with no food intake during the rest of the day. In animals, TRE improves metabolic function without caloric restriction.
- Trial name
- Rhythm (NCT07820384)
- Testing
- Time restricted eating, Healthy Eating, Extended eating window
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM.
- Trial name
- NCT00376038
- Testing
- GSK189075 oral tablets, metformin tablets
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline
Diabetes
Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women
The overall goal of this randomized controlled trial is to test the efficacy of a culturally and linguistically modified, individually tailored lifestyle intervention to reduce excess gestational weight gain (GWG), increase…
- Trial name
- NCT01868230
- Testing
- Lifestyle Intervention
- Where
- United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Amherst
Overweight and Obesity, Prediabetes
Effects of Biofunctional Orange Juice on Cardiometabolic Risk Markers
The effects of orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) compared to conventional orange juice on several cardiometabolic and…
- Conditions
- Overweight and Obesity, Prediabetes, Hypertension, Dyslipidemias
- Trial name
- NCT06114576
- Testing
- Orange juice enriched with vitamin D3 and encapsulated probiotics, Conventional orange juice
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Agricultural University of Athens
Obesity
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
This is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes.
- Trial name
- NCT07521631
- Testing
- HDM1005 dose level 1, HDM1005 dose level 2, HDM1005 dose level 3
- Where
- China
- Volunteers
- 372 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
- Trial name
- NCT07172867
- Testing
- HT-6184, Semaglutide 1 mg
- Where
- United Arab Emirates
- Sponsor
- Halia Therapeutics, Inc.
Type 2 Diabetes Mellitus
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532.
- Trial name
- NCT05158244
- Testing
- PF-07081532
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pfizer